Featured Items
Check out the Kymanox brochure on Quality and Regulatory Compliance.
Improved FDA Interactions
Kymanox helps eliminate the ambiguity surrounding regulations and published guidance to make end-requirements clear. Once this clarity is established, interactions with the FDA can be efficient and productive. Kymanox operates effectively in both proactive and reactive situations. We have expertise in organizing data for FDA review and assembling logical and thorough explanations on complex and involved issues. Both the guidance we provide and work we get done is based on a strong foundation of previous experience with the FDA:
- IND, NDA, BLA, PMA and 510k Submissions
- Inspections and Audits including Pre-Approval Inspections (PAIs)
- Responses to Deficiency, Observation (i.e., 483), and Warning Letters
- DQ/IQ/OQ/PQ Validation
Minimize Setbacks
With Kymanox involved early on, Quality Assurance and Regulatory Affairs will have the proper resources to be more proactive. Early engagement helps avoid a majority of potential issues that may impact the overall program, patient safety or product efficacy.
